NMD4C Investigators Submit Response to CDA Draft Guidance on NBS
On behalf of its Newborn Screening (NBS) Advisory Panel, Canada’s Drug Agency (CDA) recently published a discussion paper outlining its approach for developing Canadian newborn screening guidance. The goal of this discussion paper is to outline the foundations for a set of national guidelines for provincial and territorial governments to inform the development of their NBS programs. CDA have issued a call for input in response to this paper, providing an opportunity for the Canadian healthcare community to help shape the formation of these national NBS guidelines.
A group of NMD4C investigators submitted a response to this discussion paper, led by network co-lead Dr. Homira Osman, with input from neuromuscular experts including Dr. James Dowling, Dr. Hanns Lochmüller, Dr. Alex MacKenzie, Dr. Hugh McMillan, Dr. Maryam Oskoui, Dr. Kathryn Selby and Dr. Pranesh Chakraborty.
The author group noted that while the discussion paper from the CDA outlines important aspects of newborn screening, it fails to address critical issues related to infrastructure, national standards, and the integration of emerging technologies. The group identified that a broader approach is needed—one that encourages innovation, addresses systemic lab issues, and ensures equitable implementation across all provinces.
The authors recommended the creation of a national framework that sets minimum standards while allowing for the necessary flexibility to adopt new treatments and technologies as they become available. The system must be prepared for the future, and free from rigid processes that prevent timely advancements.
For any questions about future group recommendations from the network, please contact Dr. Homira Osman at .
Read next...
Muscular Dystrophy Canada Launches Initiative to Improve Genetic Testing Access for Myotonic Dystrophy
Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.
New Content Available in LEARNMD
LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. We’re excited to share what’s new on LEARNMD in February 2025!
Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group
We are thrilled to announce that the RQAS, a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy has officially become a sub-group Community of Practice of the NMD4C
NMD4C 2024 Year in Review
This year in review outlines a collection of achievements from the network over the past year.
NMD4C and MDC Award Fellowship Funding in NMD Research and Medicine
Together the Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are excited to announce the 2025 recipients of our neuromuscular fellowship funding competition to award postdoctoral fellowships in neuromuscular disease (NMD) research and clinical fellowships in neuromuscular medicine and electromyography!
NMD4C Basic Science Trainee Committee Provides Leadership Opportunity for Next Generation of Neuromuscular Researchers
The newly-formed Basic Science Trainee Committee represents the interests of trainees within the network, offering an opportunity for professional growth for future leaders in neuromuscular research.